The EndoBarrier Device: A 3-year Follow up Study
The Effect of the EndoBarrier Device: A 3-year Follow up of a Randomized Clinical Trial
Descripción general del estudio
Descripción detallada
In this observational follow-up study of a randomised clinical trial a maximum of 29 study participants may be included. These study participants were previously enrolled in the EndoBarrier device study at the MUMC or the Atrium Medical Centre Heerlen. The focus of this study lays on the long-term outcomes measured by EWL, postoperative blood sampling and questionnaires. These measurements, samples and questionnaires will be taken to assess the long-term effectiveness of the EndoBarrier device in the treatment of morbid obesity. Participants who were previously enrolled in the EndoBarrier device study at the MUMC or at the Atrium Medical Centre in Heerlen and who have agreed to participate in this study will be requested to arrive at the outpatient clinic of the MUMC after an overnight fast. Blood sample will be taken for total cholesterol, HDL, LDL, triglycerides, Hb, Ht, iron, HbA1c, insulin levels, glucose, amylase, lipase, C-peptide, Creatinine, vitamin D, Calcium, ALAT, ASAT, AF, gamma GT, albumin, CK-18, L-FABP, FGF19, Total bile salts and bile salt composition. These parameters are associated with risk factors in morbid obesity namely: Nonalcoholic Fatty Liver disease, hypertension, diabetes mellitus type II (DMII), coronary heart disease and osteoarthritis. After the blood sampling, physical health will be assessed by means of standard physical examination (weight, waist size, length, blood pressure, heart rate, breathing frequency). Then, the participant will be requested to fill in a validated questionnaire. In this study the SF-36 quality of life questionnaire will be used. This is a validated questionnaire assessing non-specific symptoms and quality of life after Bariatric surgery.
Three years of follow-up after the EndoBarrier device is now available. The investigators hope to give new insights in the postoperative status and postoperative symptoms experienced by participants using standardised questionnaires and evaluating blood samples. The goal of the investigators is to study the long-term effect of the EndoBarrier procedure and to possibly provide insight in the relation between success/failure and objective parameters.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Limburg
-
Maastricht, Limburg, Países Bajos, 6229 HX
- Maastricht University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen regardless of their excess weight loss.
- Participants who have a follow up of at least 3 years.
- Signed informed consent.
Exclusion Criteria:
- Post-EndoBarrier conventional bariatric surgery
- Participants who were lost to follow-up during the previous conducted EndoBarrier clinical trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
EndoBarrier
Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
|
The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through.
The sleeve is anchored in the duodenal bulb and extends partially into the jejunum.
This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Excess Weight (%)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Insulin levels (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Total Cholesterol (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
SF-36 health related quality of life, patient-reported survey of patient health
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
36 months post explant EndoBarrier Liner
|
|
FGF 19 (ng/ml)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
ASAT (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Amylase (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Systolic blood pressure (mmHg)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
BMI (Kg/M2)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Diastolic blood pressure (mmHg)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
glucose levels (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
HbA1c level (%)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Triglycerides (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
HDL (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
LDL (mmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
L-FABP (ng/ml)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Lipase (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
ALAT (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
AF (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
GammaGT (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
Albumin (g/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
CK-18 (U/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
|
|
C-peptide (nmol/L)
Periodo de tiempo: 36 months post explant EndoBarrier Liner
|
36 months post explant EndoBarrier Liner
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Nicole Bouvy, MD, PhD, Maastricht University Medical Center, The Netherlands
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- NL51074.068.14
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre EndoBarrier
-
GI DynamicsTerminadoDiabetes tipo 2Brasil
-
GI DynamicsBiostatistical Consulting, Inc.ReclutamientoObesidad | Diabetes tipo 2Estados Unidos
-
GI DynamicsTerminado
-
University Hospital, LilleMinistry of Health, FranceTerminadoSíndrome metabólicoFrancia
-
GI DynamicsTerminadoObesidad | Diabetes tipo 2Reino Unido
-
GI DynamicsTerminado
-
GI DynamicsTerminadoObesidad | Diabetes tipo 2Brasil
-
GI DynamicsTerminado
-
GI DynamicsTerminado